Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases

被引:105
|
作者
Fleck, C [1 ]
Schweitzer, F
Karge, E
Busch, M
Stein, G
机构
[1] Univ Jena, Inst Pharmacol & Toxicol, D-07740 Jena, Germany
[2] Univ Jena, Dept Internal Med 3, Jena, Germany
关键词
kidney disease; chronic renal failure; end stage renal disease; renal transplantation; dimethylarginines; ADMA; SDMA; hypertension; diabetes mellitus; atherosclerosis;
D O I
10.1016/S0009-8981(03)00338-3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: NO synthesis is inhibited by the dimethylarginine (DMA) ADMA, which accumulates, similar to SDMA, in the plasma of patients suffering from chronic renal failure (CRF). ADMA and possibly SDMA contribute to hypertension and atherosclerosis in patients with chronic renal disease: ADMA inhibits directly eNOS, whereas SDMA competes with the NO precursor arginine for uptake into the cells. Methods: In 26 control persons and 221 patients with kidney diseases of different stage as were CRF, end stage renal disease (ESRD), and patients after renal transplantation (RT), the plasma concentrations of ADMA (c(ADMA) SDMA (c(SDMA)) and 20 endogenous amino acids (AA) were measured by HPLC and correlated to blood pressure, cardiac events, endothelial dysfunction, and diabetes mellitus. Results: Both ADMA (1.04 +/- 0.04 vs. 0.66 +/- 0.04 muM) and SDMA (2.69 +/- 0.12 vs. 0.49 +/- 0.03 muM) were significantly (p < 0.001) elevated in all patients compared to healthy controls, whereas arginine concentration (51.4 +/- 23 vs. 76.0 +/- 5.2 muM) was decreased in dependence on the degree of kidney disease. In RT patients, SDMA levels were significantly decreased, but c(ADMA) remained enhanced. A strong correlation was found between SDMA and both serum urea and creatinine in CRF and RT patients. A linear correlation was found between ADMA and cholesterol concentrations in RT patients. Hypertension in CRF was accompanied by a further increase in the concentration of DMAs. There was no relation between DMAs and the occurrence of peripheral arterial occlusive disease or cerebrovascular diseases. In patients with cardiac diseases, c(SDMA) was additionally increased only in the CRF group. Conclusions: In patients with chronic kidney disease, c(ADMA) and c(SDMA) are significantly increased but cardiovascular diseases are evidently not correlated to changes in DMA concentrations in this group of patients. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients
    Fleck, C
    Janz, A
    Schweitzer, F
    Karge, E
    Schwertfeger, M
    Stein, G
    KIDNEY INTERNATIONAL, 2001, 59 : S14 - S18
  • [2] Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes
    Tsikas, Dimitrios
    Bollenbach, Alexander
    Hanff, Erik
    Kayacelebi, Arslan Arinc
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [3] Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes
    Dimitrios Tsikas
    Alexander Bollenbach
    Erik Hanff
    Arslan Arinc Kayacelebi
    Cardiovascular Diabetology, 17
  • [4] Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
    Tain, You-Lin
    Hsu, Chien-Ning
    TOXINS, 2017, 9 (03):
  • [5] ELEVATED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) AND SYMMETRIC DIMETHYLARGININE (SDMA) CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS
    Landray, Martin J.
    Dalton, Neil
    Turner, Charles
    Blackwell, Lisa
    Morgan, Matthew
    Nuttall, Sarah
    Baigent, Colin
    Townend, John
    Wheeler, David C.
    NEPHROLOGY, 2005, 10 : A152 - A152
  • [6] Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA) Concentrations in Patients with Obesity and the Risk of Obstructive Sleep Apnea (OSA)
    Arlouskaya, Yana
    Sawicka, Ada
    Glowala, Marek
    Giebultowicz, Joanna
    Korytowska, Natalia
    Talalaj, Marek
    Nowicka, Grazyna
    Wrzosek, Malgorzata
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [7] Evaluation of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in patient with erectile dysfunction
    Barassi, A.
    Paroni, R.
    Fermo, I.
    Biondi, M. L.
    Pavlovic, R.
    Piediferro, G.
    Colpi, G. M.
    d'Eril, G. V. Melzi
    CLINICAL CHEMISTRY, 2007, 53 (06) : A171 - A171
  • [8] The Effect of Fasting on Serum Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA): A Report from a Large Reference Laboratory
    Albeiroti, S.
    Winchester, T.
    CLINICAL CHEMISTRY, 2024, 70
  • [9] Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach
    Oliva-Damaso, Elena
    Oliva-Damaso, Nestor
    Rodriguez-Esparragon, Francisco
    Payan, Juan
    Baamonde-Laborda, Eduardo
    Gonzalez-Cabrera, Fayna
    Santana-Estupinan, Raquel
    Carlos Rodriguez-Perez, Jose
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (15)
  • [10] Determination of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in human plasma: analytical and clinical validation
    Plebani, M.
    Artusi, C.
    Ivanova, M.
    Boffa, G.
    Zaninotto, M.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A199 - A199